株探米国株
日本語 英語
エドガーで原本を確認する
0000001800FALSENew York Stock ExchangeChicago Stock Exchange, Inc.00000018002024-10-162024-10-160000001800exch:XNYS2024-10-162024-10-160000001800exch:XCHI2024-10-162024-10-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
October 16, 2024
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________

Illinois 1-2189 36-0698440
(State or other Jurisdiction
of Incorporation)		 (Commission File Number) (IRS Employer
Identification  No.)
_______________________________________________________
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Shares, Without Par Value ABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o On October 16, 2024, Abbott Laboratories announced its results of operations for the third quarter 2024.


Item 2.02    Results of Operations and Financial Condition
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, cost reduction initiatives, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01    Financial Statements and Exhibits
Exhibit No. Exhibit
104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: October 16, 2024 By: /s/ Philip P. Boudreau
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer

EX-99.1 2 abt-2024q3xexhibitx991.htm EX-99.1 Document

Exhibit 99.1 1
abbottlogoa.jpg
  News Release

Abbott Reports Third-Quarter 2024 Results and Raises Midpoint of Full-Year EPS Guidance Range

–Sales of $10.6 billion driven by strong underlying base business performance
–Reported sales growth of 4.9 percent; organic sales growth for underlying base business of 8.2 percent1, led by double-digit growth in Medical Devices
–Continues to strengthen portfolio with steady cadence of new product approvals, reimbursement coverage, and clinical data
ABBOTT PARK, Ill., Oct. 16, 2024 — Abbott today announced financial results for the third quarter ended Sept. 30, 2024.

•Third-quarter GAAP diluted EPS of $0.94 and adjusted diluted EPS of $1.21, which excludes specified items.
•Abbott maintains its full-year 2024 organic sales growth guidance range of 9.5% to 10.0%, excluding COVID-19 testing-related sales2.
•Abbott now projects full-year diluted EPS on a GAAP basis of $3.34 to $3.40 and projects adjusted diluted EPS of $4.64 to $4.70, which represents an increase at the midpoint of the guidance range.
•In October, Abbott's board of directors authorized a new share repurchase program of up to $7 billion of the company's common shares.
•In August, Abbott announced a unique global partnership with Medtronic to collaborate on connecting Abbott's world-leading continuous glucose monitoring (CGM) system with Medtronic's insulin delivery devices.
•In September, Abbott announced the U.S. launch of Lingo™, the company's first continuous glucose monitoring system available without a prescription and designed for people interested in improving their overall health and wellness.
•In September, Abbott announced a partnership with the Big Ten Conference® to conduct a nationwide blood donation competition to help increase the U.S. blood supply.
•In September, Abbott completed enrollment ahead of schedule in its VOLT-AF IDE trial, which is designed to evaluate the Volt™ Pulsed Field Ablation (PFA) System for treating patients with heart rhythm disorders such as atrial fibrillation (AFib).


"Our results this quarter demonstrate the strength of our diversified business model," said Robert B. Ford, chairman and chief executive officer, Abbott. "We're well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year." Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business.
-- more -- 
Page 1 of 20

THIRD-QUARTER BUSINESS OVERVIEW
Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.


Third Quarter 2024 Results (3Q24)
Sales 3Q24 ($ in millions)
 Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices
U.S. 4,202  950  1,032  —  2,216 
International 6,433  1,116  1,380  1,406  2,531 
Total reported 10,635  2,066  2,412  1,406  4,747 
% Change vs. 3Q23
U.S. 10.1  10.4  1.8  n/a 14.2 
International 1.7  (7.9) (3.8) 2.7  9.6 
Total reported 4.9  (0.3) (1.5) 2.7  11.7 
Impact of foreign exchange (2.5) (3.1) (2.9) (4.3) (1.6)
Impact of business exit*
 (0.2) (0.6) —  —  — 
Organic 7.6  3.4  1.4  7.0  13.3 
Impact of COVID-19 testing sales (3)
 (0.6) —  (1.9) —  — 
Organic (excluding COVID-19 tests) 8.2  3.4  3.3  7.0  13.3 
    U.S. 11.0  11.9  2.4  n/a 14.2 
    International 6.5  (2.6) 3.8  7.0  12.5 

First Nine Months 2024 Results (9M24)
Sales 9M24 ($ in millions)
 Total Company Nutrition Diagnostics Established Pharmaceuticals Medical Devices
U.S. 11,982  2,761  2,775  —  6,435 
International 18,994  3,523  4,046  3,926  7,499 
Total reported 30,976  6,284  6,821  3,926  13,934 
% Change vs. 9M23
U.S. 4.2  8.1  (16.2) n/a 14.3 
International 3.4  (1.1) (2.4) 2.1  10.1 
Total reported 3.7  2.7  (8.5) 2.1  12.0 
Impact of foreign exchange (3.0) (3.1) (2.9) (7.3) (1.6)
Impact of business exit and acquisition*
 0.1  (0.4) —  —  0.4 
Organic 6.6  6.2  (5.6) 9.4  13.2 
Impact of COVID-19 testing sales (3)
 (2.8) —  (10.4) —  — 
Organic (excluding COVID-19 tests) 9.4  6.2  4.8  9.4  13.2 
    U.S. 10.0  9.0  3.0  n/a 13.3 
    International 9.0  4.2  5.9  9.4  13.1 
Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.
*Quarter to date Sept. 30, 2024, reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024. Year to date Sept. 30, 2024, reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in March 2024 and the acquisition of CSI on April 27, 2023. Organic sales growth excludes the impact of the acquired business from January through April 2024.
-- more --
Page 2 of 20


Nutrition

Third Quarter 2024 Results (3Q24)

Sales 3Q24 ($ in millions)
 Total Pediatric Adult
U.S. 950  568  382 
International 1,116  387  729 
Total reported 2,066  955  1,111 
% Change vs. 3Q23
U.S. 10.4  12.2  7.9 
International (7.9) (21.6) 1.5 
Total reported (0.3) (4.5) 3.6 
Impact of foreign exchange (3.1) (1.8) (4.4)
Impact of business exit*
 (0.6) —  (1.1)
Organic 3.4  (2.7) 9.1 
    U.S. 11.9  12.2  11.5 
    International (2.6) (18.0) 8.0 
Worldwide Nutrition sales decreased 0.3 percent on a reported basis and increased 3.4 percent on an organic basis in the third quarter, led by growth in Adult Nutrition.
In Adult Nutrition, global sales increased 3.6 percent on a reported basis and 9.1 percent on an organic basis, which was led by growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand.


First Nine Months 2024 Results (9M24)

Sales 9M24 ($ in millions)
 Total Pediatric Adult
U.S. 2,761  1,646  1,115 
International 3,523  1,377  2,146 
Total reported 6,284  3,023  3,261 
% Change vs. 9M23
U.S. 8.1  11.8  3.2 
International (1.1) (6.8) 2.8 
Total reported 2.7  2.5  3.0 
Impact of foreign exchange (3.1) (1.6) (4.4)
Impact of business exit* (0.4) —  (0.7)
Organic 6.2  4.1  8.1 
    U.S. 9.0  11.8  5.0 
    International 4.2  (3.6) 9.7 
*Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in March 2024.

-- more --
Page 3 of 20


Diagnostics

Third Quarter 2024 Results (3Q24)
Sales 3Q24 ($ in millions)
 Total Core Laboratory Molecular Point of Care Rapid Diagnostics
U.S. 1,032  332  37  103  560 
International 1,380  982  91  43  264 
Total reported 2,412  1,314  128  146  824 
% Change vs. 3Q23
U.S. 1.8  4.5  (2.8) 6.0  (0.2)
International (3.8) (1.5) (3.9) 0.7  (12.2)
Total reported (1.5) —  (3.6) 4.4  (4.4)
Impact of foreign exchange (2.9) (4.3) (1.5) (0.2) (1.4)
Organic 1.4  4.3  (2.1) 4.6  (3.0)
Impact of COVID-19 testing sales (3)
(1.9) (0.2) (3.9) —  (3.4)
Organic (excluding COVID-19 tests) 3.3  4.5  1.8  4.6  0.4 
    U.S. 2.4  4.8  4.5  6.0  (1.0)
    International 3.8  4.4  0.8  1.3  2.8 

As expected, Diagnostics sales growth in the third quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales3. Worldwide COVID-19 testing sales were $265 million in the third quarter of 2024 compared to $305 million in the third quarter of the prior year.

Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2 percent on a reported basis and increased 3.3 percent on an organic basis.

Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales grew 0.1 percent on a reported basis and increased 4.5 percent on an organic basis, led by continued adoption of Abbott's Alinity® family of diagnostics systems and testing portfolios.


First Nine Months 2024 Results (9M24)
Sales 9M24 ($ in millions)
 Total Core Laboratory Molecular Point of Care Rapid Diagnostics
U.S. 2,775  969  112  308  1,386 
International 4,046  2,879  272  133  762 
Total reported 6,821  3,848  384  441  2,148 
% Change vs. 9M23
U.S. (16.2) 5.6  (12.3) 6.6  (29.8)
International (2.4) 0.3  (7.2) 4.8  (10.6)
Total reported (8.5) 1.5  (8.7) 6.0  (24.0)
Impact of foreign exchange (2.9) (4.8) (0.8) (0.1) (1.1)
Organic (5.6) 6.3  (7.9) 6.1  (22.9)
Impact of COVID-19 testing sales (3)
 (10.4) (0.2) (6.3) —  (25.0)
Organic (excluding COVID-19 tests) 4.8  6.5  (1.6) 6.1  2.1 
    U.S. 3.0  5.9  (3.3) 6.6  (0.1)
    International 5.9  6.7  (0.9) 5.1  5.7 



-- more --
Page 4 of 20


Established Pharmaceuticals

Third Quarter 2024 Results (3Q24)
Sales 3Q24 ($ in millions)
 Total Key Emerging Markets Other
U.S. —  —  — 
International 1,406  994  412 
Total reported 1,406  994  412 
% Change vs. 3Q23
U.S. n/a n/a n/a
International 2.7  0.7  8.1 
Total reported 2.7  0.7  8.1 
Impact of foreign exchange (4.3) (4.7) (3.1)
Organic 7.0  5.4  11.2 
    U.S. n/a n/a n/a
    International 7.0  5.4  11.2 

Established Pharmaceuticals sales increased 2.7 percent on a reported basis and 7.0 percent on an organic basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 0.7 percent on a reported basis and increased 5.4 percent on an organic basis, led by growth in several geographies and therapeutic areas, including gastroenterology, cardiometabolic, and central nervous system/pain management.


First Nine Months 2024 Results (9M24)
Sales 9M24 ($ in millions)
 Total Key Emerging Markets Other
U.S. —  —  — 
International 3,926  2,910  1,016 
Total reported 3,926  2,910  1,016 
% Change vs. 9M23
U.S. n/a n/a n/a
International 2.1  0.7  6.4 
Total reported 2.1  0.7  6.4 
Impact of foreign exchange (7.3) (9.0) (2.2)
Organic 9.4  9.7  8.6 
    U.S. n/a n/a n/a
    International 9.4  9.7  8.6 











-- more --
Page 5 of 20


Medical Devices

Third Quarter 2024 Results (3Q24)
Sales 3Q24 ($ in millions)
 Total Rhythm Management Electro-
physiology		 Heart Failure Vascular Structural Heart Neuro-modulation Diabetes Care
U.S. 2,216  288  285  252  258  270  190  673 
International 2,531  309  325  70  441  288  46  1,052 
Total reported 4,747  597  610  322  699  558  236  1,725 
% Change vs. 3Q23
U.S. 14.2  6.0  15.8  16.7  2.8  21.1  0.8  23.6 
International 9.6  5.7  9.2  5.2  4.5  9.2  17.8  13.3 
Total reported 11.7  5.9  12.2  14.0  3.9  14.6  3.8  17.1 
Impact of foreign exchange (1.6) (1.1) (2.1) (0.4) (1.0) (1.9) (1.4) (2.0)
Organic 13.3  7.0  14.3  14.4  4.9  16.5  5.2  19.1 
    U.S. 14.2  6.0  15.8  16.7  2.8  21.1  0.8  23.6 
    International 12.5  7.9  13.0  6.6  6.2  12.6  25.7  16.5 

Worldwide Medical Devices sales increased 11.7 percent on a reported basis and 13.3 percent on an organic basis in the third quarter, including double-digit organic growth in both the U.S. and internationally.

Sales growth was led by double-digit growth in Diabetes Care, Structural Heart, Heart Failure, and Electrophysiology. Several products contributed to the strong performance, including FreeStyle Libre®, Navitor®, TriClip®, Amplatzer® Amulet®, and AVEIR®.

In Electrophysiology, sales grew 12.2 percent on a reported basis and 14.3 percent on an organic basis, which included double-digit growth in catheters and cardiac mapping-related products.

In Diabetes Care, sales of continuous glucose monitors exceeded $1.6 billion and grew 19.1 percent on a reported basis and 20.7 percent on an organic basis.


First Nine Months 2024 Results (9M24)
Sales 9M24 ($ in millions)
 Total Rhythm Management Electro-
physiology		 Heart Failure Vascular Structural Heart Neuro-modulation Diabetes Care
U.S. 6,435  851  841  733  787  761  563  1,899 
International 7,499  915  983  215  1,325  876  142  3,043 
Total reported 13,934  1,766  1,824  948  2,112  1,637  705  4,942 
% Change vs. 9M23
U.S. 14.3  6.4  15.3  11.0  7.4  16.7  6.5  24.3 
International 10.1  4.8  12.6  8.2  4.2  10.3  16.5  13.5 
Total reported 12.0  5.6  13.8  10.4  5.4  13.2  8.4  17.4 
Impact of foreign exchange (1.6) (1.2) (2.6) (0.1) (1.3) (1.9) (1.5) (1.9)
Impact of acquisition* 0.4  —  —  —  2.8  —  —  — 
Organic 13.2  6.8  16.4  10.5  3.9  15.1  9.9  19.3 
    U.S. 13.3  6.4  15.3  11.0  0.1  16.7  6.5  24.3 
    International 13.1  7.1  17.4  8.9  6.0  13.7  24.6  16.5 

*Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.

-- more --
Page 6 of 20


ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.34 to $3.40. Abbott forecasts specified items for the full-year 2024 of $1.30 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.64 to $4.70 for the full-year 2024.

Abbott projects fourth-quarter 2024 diluted earnings per share under GAAP of $0.96 to $1.02. Abbott forecasts specified items for the fourth-quarter 2024 of $0.35 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $1.31 to $1.37 for the fourth quarter 2024.
ABBOTT DECLARES 403RD CONSECUTIVE QUARTERLY DIVIDEND
On Sept. 19, 2024, the board of directors of Abbott declared the company's quarterly dividend of $0.55 per share. Abbott's cash dividend is payable Nov. 15, 2024, to shareholders of record at the close of business on Oct. 15, 2024.

Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.


About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
-- more --
Page 7 of 20


— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika LeBean, 224-399-5082
Ryan Aliff, 224-667-2299
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965
1In the third quarter of 2024, total worldwide sales were $10.635 billion and COVID-19 testing-related sales were $265 million. In the third quarter of 2023, total worldwide sales were $10.143 billion and COVID-19 testing-related sales were $305 million.

2Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests.


3Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below:
Sales 3Q24 COVID Tests Sales 3Q24
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 1,032  1,380  2,412  206  59  265 
Core Laboratory 332  982  1,314  1  2  3 
Molecular 37  91  128  2  1  3 
Rapid Diagnostics 560  264  824  203  56  259 
Sales 3Q23 COVID Tests Sales 3Q23
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 1,013  1,436  2,449  207  98  305 
Core Laboratory 317  997  1,314  2  3  5 
Molecular 38  95  133  5  3  8 
Rapid Diagnostics 561  301  862  200  92  292 

Sales 9M24 COVID Tests Sales 9M24
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 2,775  4,046  6,821  428  143  571 
Core Laboratory 969  2,879  3,848  3  5  8 
Molecular 112  272  384  7  3  10 
Rapid Diagnostics 1,386  762  2,148  418  135  553 
Sales 9M23 COVID Tests Sales 9M23
($ in millions) U.S. Int'l Total U.S. Int'l Total
Total Diagnostics 3,309  4,145  7,454  1,031  267  1,298 
Core Laboratory 917  2,872  3,789  6  10  16 
Molecular 128  293  421  19  17  36 
Rapid Diagnostics 1,975  853  2,828  1,006  240  1,246 

-- more --
Page 8 of 20


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Third Quarter Ended September 30, 2024 and 2023
(in millions, except per share data)
(unaudited)




3Q24 3Q23 % Change
Net Sales $10,635 $10,143 4.9 
Cost of products sold, excluding amortization expense 4,698  4,605  2.0 
Amortization of intangible assets 470  496  (5.1)
Research and development 713  672  6.1 
Selling, general, and administrative 2,895  2,723  6.3 
Total Operating Cost and Expenses 8,776  8,496  3.3 
Operating Earnings 1,859  1,647  12.8 
Interest expense, net 51  69  (26.0)
Net foreign exchange (gain) loss (11) (10) n/m
Other (income) expense, net (121) (83) n/m
Earnings before taxes 1,940  1,671  16.1 
Taxes on earnings 294  235  25.6 
Net Earnings $1,646 $1,436 14.6 
Net Earnings excluding Specified Items, as described below $2,119 $2,000 5.9  1)
Diluted Earnings per Common Share $0.94 $0.82 14.6 
Diluted Earnings per Common Share,
excluding Specified Items, as described below
 $1.21 $1.14 6.1  1)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
 1,748  1,748 


NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 9 of 20


1)2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $473 million, or $0.27 per share, for intangible amortization, charges related to intangible impairment, expenses associated with acquisitions and a divestiture, and other net expenses.

2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $564 million, or $0.32 per share, for intangible amortization, charges related to the impairment of R&D intangible assets, expenses associated with acquisitions, restructuring and cost reduction initiatives and other net expenses.
-- more --
Page 10 of 20


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Nine Months Ended September 30, 2024 and 2023
(in millions, except per share data)
(unaudited)




9M24 9M23 % Change
Net Sales $30,976 $29,868 3.7 
Cost of products sold, excluding amortization expense 13,764  13,419  2.6 
Amortization of intangible assets 1,413  1,485  (4.9)
Research and development 2,095  2,041  2.6 
Selling, general, and administrative 8,790  8,225  6.9 
Total Operating Cost and Expenses 26,062  25,170  3.5 
Operating Earnings 4,914  4,698  4.6 
Interest expense, net 170  182  (6.4)
Net foreign exchange (gain) loss (17) 17  n/m
Other (income) expense, net (222) (370) n/m
Earnings before taxes 4,983  4,869  2.3 
Taxes on earnings 810  740  9.6  1)
Net Earnings $4,173 $4,129 1.0 
Net Earnings excluding Specified Items, as described below $5,851 $5,708 2.5  2)
Diluted Earnings per Common Share $2.38 $2.35 1.3 
Diluted Earnings per Common Share,
excluding Specified Items, as described below
 $3.33 $3.25 2.5  2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
 1,749  1,750 



NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 11 of 20


1)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2023 Taxes on Earnings includes the recognition of approximately $59 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.678 billion, or $0.95 per share, for intangible amortization, charges related to intangible impairment, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.

2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.579 billion, or $0.90 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

-- more --
Page 12 of 20


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Third Quarter Ended September 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
3Q24
As
Reported (GAAP)		 Specified Items As
Adjusted
Intangible Amortization
 $ 470  $ (470) $ — 
Gross Margin
 5,467  516  5,983 
R&D
 713  (19) 694 
SG&A
 2,895  (5) 2,890 
Other (income) expense, net
 (121) (12) (133)
Earnings before taxes
 1,940  552  2,492 
Taxes on Earnings
 294  79  373 
Net Earnings
 1,646  473  2,119 
Diluted Earnings per Share
 $ 0.94  $ 0.27  $ 1.21 

Specified items reflect intangible amortization expense of $470 million and other net expenses of $82 million associated with charges related to intangible impairment, acquisitions, a divestiture and other net expenses. See page 17 for additional details regarding specified items.
3Q23
As
Reported (GAAP)		 Specified Items As
Adjusted
Intangible Amortization
 $ 496  $ (496) $ — 
Gross Margin
 5,042  542  5,584 
R&D
 672  (46) 626 
SG&A
 2,723  (43) 2,680 
Other (income) expense, net
 (83) (23) (106)
Earnings before taxes
 1,671  654  2,325 
Taxes on Earnings
 235  90  325 
Net Earnings
 1,436  564  2,000 
Diluted Earnings per Share
 $ 0.82  $ 0.32  $ 1.14 

Specified items reflect intangible amortization expense of $496 million and other net expenses of $158 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See page 18 for additional details regarding specified items.
-- more --
Page 13 of 20


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Nine Months Ended September 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
9M24
As
Reported (GAAP)		 Specified Items As
Adjusted
Intangible Amortization
 $ 1,413  $ (1,413) $ — 
Gross Margin
 15,799  1,540  17,339 
R&D
 2,095  (81) 2,014 
SG&A
 8,790  (96) 8,694 
Other (income) expense, net
 (222) (183) (405)
Earnings before taxes
 4,983  1,900  6,883 
Taxes on Earnings
 810  222  1,032 
Net Earnings
 4,173  1,678  5,851 
Diluted Earnings per Share
 $ 2.38  $ 0.95  $ 3.33 

Specified items reflect intangible amortization expense of $1.413 billion and other net expenses of $487 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 19 for additional details regarding specified items.
9M23
As
Reported (GAAP)		 Specified Items As
Adjusted
Intangible Amortization
 $ 1,485  $ (1,485) $ — 
Gross Margin
 14,964  1,591  16,555 
R&D
 2,041  (144) 1,897 
SG&A
 8,225  (67) 8,158 
Other (income) expense, net
 (370) 34  (336)
Earnings before taxes
 4,869  1,768  6,637 
Taxes on Earnings
 740  189  929 
Net Earnings
 4,129  1,579  5,708 
Diluted Earnings per Share
 $ 2.35  $ 0.90  $ 3.25 

Specified items reflect intangible amortization expense of $1.485 billion and other net expenses of $283 million associated with restructuring actions, costs associated with acquisitions and other expenses. See page 20 for additional details regarding specified items.

-- more --
Page 14 of 20


A reconciliation of the third-quarter tax rates for 2024 and 2023 is shown below:
3Q24
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 1,940  $ 294  15.2  %
Specified items 552  79 
Excluding specified items $ 2,492  $ 373  15.0  %
3Q23
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 1,671  $ 235  14.0  %
Specified items 654  90 
Excluding specified items $ 2,325  $ 325  14.0  %

A reconciliation of the year-to-date tax rates for 2024 and 2023 is shown below:
9M24
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 4,983  $ 810  16.3  % 1)
Specified items 1,900  222 
Excluding specified items $ 6,883  $ 1,032  15.0  %
9M23
($ in millions) Pre-Tax
Income		 Taxes on
Earnings		 Tax
Rate
As reported (GAAP) $ 4,869  $ 740  15.2  % 2)
Specified items 1,768  189 
Excluding specified items $ 6,637  $ 929  14.0  %

1)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2023 Taxes on Earnings includes the recognition of approximately $59 million of net tax expense as a result of the resolution of various tax positions related to prior years.


-- more --
Page 15 of 20


Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Third Quarter and Nine Months Ended September 30, 2024 and 2023
($ in millions)
(unaudited)
3Q24 3Q23 % Change vs. 3Q23
Non-GAAP
Abbott Reported Impact from business exit (b) Adjusted Revenue Abbott Reported Impact from business exit (b) Adjusted Revenue Reported Adjusted Organic
Total Company 10,635  (5) 10,630  10,143  (17) 10,126  4.9  5.1  7.6 
U.S. 4,202  (5) 4,197  3,817  (17) 3,800  10.1  10.4  10.4 
Intl 6,433  —  6,433  6,326  —  6,326  1.7  1.7  5.8 
Total Nutrition 2,066  (5) 2,061  2,073  (17) 2,056  (0.3) 0.3  3.4 
U.S. 950  (5) 945  860  (17) 843  10.4  11.9  11.9 
Intl 1,116  —  1,116  1,213  —  1,213  (7.9) (7.9) (2.6)
Adult Nutrition 1,111  (5) 1,106  1,072  (17) 1,055  3.6  4.7  9.1 
U.S. 382  (5) 377  354  (17) 337  7.9  11.5  11.5 
Intl 729  —  729  718  —  718  1.5  1.5  8.0 
Total Medical Devices 4,747  —  4,747  4,249  —  4,249  11.7  11.7  13.3 
U.S. 2,216  —  2,216  1,940  —  1,940  14.2  14.2  14.2 
Intl 2,531  —  2,531  2,309  —  2,309  9.6  9.6  12.5 
Vascular 699  —  699  672  —  672  3.9  3.9  4.9 
U.S. 258  —  258  251  —  251  2.8  2.8  2.8 
Intl 441  —  441  421  —  421  4.5  4.5  6.2 
9M24 9M23 % Change vs. 9M23
Non-GAAP
Abbott Reported Impact of acquisition (a) Impact from business exit (b) Adjusted Revenue Abbott Reported Impact from business exit (b) Adjusted Revenue Reported Adjusted Organic
Total Company 30,976  (57) (13) 30,906  29,868  (32) 29,836  3.7  3.6  6.6 
U.S. 11,982  (53) (13) 11,916  11,503  (32) 11,471  4.2  3.9  3.9 
Intl 18,994  (4) —  18,990  18,365  —  18,365  3.4  3.4  8.3 
Total Nutrition 6,284  —  (13) 6,271  6,116  (32) 6,084  2.7  3.1  6.2 
U.S. 2,761  —  (13) 2,748  2,553  (32) 2,521  8.1  9.0  9.0 
Intl 3,523  —  —  3,523  3,563  —  3,563  (1.1) (1.1) 4.2 
Adult Nutrition 3,261  —  (13) 3,248  3,167  (32) 3,135  3.0  3.7  8.1 
U.S. 1,115  —  (13) 1,102  1,081  (32) 1,049  3.2  5.0  5.0 
Intl 2,146  —  —  2,146  2,086  —  2,086  2.8  2.8  9.7 
Total Medical Devices 13,934  (57) —  13,877  12,444  —  12,444  12.0  11.6  13.2 
U.S. 6,435  (53) —  6,382  5,631  —  5,631  14.3  13.3  13.3 
Intl 7,499  (4) —  7,495  6,813  —  6,813  10.1  10.0  13.1 
Vascular 2,112  (57) —  2,055  2,004  —  2,004  5.4  2.6  3.9 
U.S. 787  (53) —  734  733  —  733  7.4  0.1  0.1 
Intl 1,325  (4) —  1,321  1,271  —  1,271  4.2  3.9  6.0 

(a) Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.
(b) Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.

-- more --
Page 16 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2024
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		 Restructuring
and Cost
Reduction
Initiatives (b)		 Intangible
Amortization		 Other (c) Total
Specifieds
Gross Margin $ —  $ 2  $ 470  $ 44  $ 516 
R&D —  —  —  (19) (19)
SG&A (7) 2  —  —  (5)
Other (income) expense, net (5) —  —  (7) (12)
Earnings before taxes $ 12  $ —  $ 470  $ 70  552 
Taxes on Earnings (d) 79 
Net Earnings $ 473 
Diluted Earnings per Share $ 0.27 
The table above provides additional details regarding the specified items described on page 13.

a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and investment and intangible asset impairment charges.
d)Reflects the net tax benefit associated with the specified items.



-- more --
Page 17 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
Third Quarter Ended September 30, 2023
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		 Restructuring
and Cost
Reduction
Initiatives (b)		 Intangible
Amortization		 Other (c) Total
Specifieds
Gross Margin $ 3  $ 19  $ 496  $ 24  $ 542 
R&D (1) (13) —  (32) (46)
SG&A (22) (22) —  1  (43)
Other (income) expense, net 5  —  —  (28) (23)
Earnings before taxes $ 21  $ 54  $ 496  $ 83  654 
Taxes on Earnings (d) 90 
Net Earnings $ 564 
Diluted Earnings per Share $ 0.32 

The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as legal and other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items.

-- more --
Page 18 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2024
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		 Restructuring
and Cost
Reduction
Initiatives (b)		 Intangible
Amortization		 Other (c) Total
Specifieds
Gross Margin $ 2  $ 76  $ 1,413  $ 49  $ 1,540 
R&D (4) (1) —  (76) (81)
SG&A (32) (17) —  (47) (96)
Other (income) expense, net (140) —  —  (43) (183)
Earnings before taxes $ 178  $ 94  $ 1,413  $ 215  1,900 
Taxes on Earnings (d) 222 
Net Earnings $ 1,678 
Diluted Earnings per Share $ 0.95 
The table above provides additional details regarding the specified items described on page 14.

a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
-- more --
Page 19 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
Nine Months Ended September 30, 2023
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		 Restructuring
and Cost
Reduction
Initiatives (b)		 Intangible
Amortization		 Other (c) Total
Specifieds
Gross Margin $ 15  $ 51  $ 1,485  $ 40  $ 1,591 
R&D (13) (5) —  (126) (144)
SG&A (43) (28) —  4  (67)
Other (income) expense, net 46  —  —  (12) 34 
Earnings before taxes $ 25  $ 84  $ 1,485  $ 174  1,768 
Taxes on Earnings (d) 189 
Net Earnings $ 1,579 
Diluted Earnings per Share $ 0.90 

The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
###
Page 20 of 20